Search Results - "Stratford, I."

Guidelines for the welfare and use of animals in cancer research by Workman, P, Aboagye, E O, Balkwill, F, Balmain, A, Bruder, G, Chaplin, D J, Double, J A, Everitt, J, Farningham, D A H, Glennie, M J, Kelland, L R, Robinson, V, Stratford, I J, Tozer, G M, Watson, S, Wedge, S R, Eccles, S A

“…Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and…”
Get full text

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers by Harrington, K J, Billingham, L J, Brunner, T B, Burnet, N G, Chan, C S, Hoskin, P, Mackay, R I, Maughan, T S, Macdougall, J, McKenna, W G, Nutting, C M, Oliver, A, Plummer, R, Stratford, I J, Illidge, T

Get full text

HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells by MAXWELL, P. J, GALLAGHER, R, SEATON, A, WILSON, C, SCULLIN, P, PETTIGREW, J, STRATFORD, I. J, WILLIAMS, K. J, JOHNSTON, P. G, WAUGH, D. J. J

“…Hypoxic cancer cells are resistant to treatment, leading to the selection of cells with a more malignant phenotype. The expression of interleukin-8 (IL-8)…”
Get full text

The impact of monocarboxylate transporter expression on metabolic function in prostate cancer cells by Hutchinson, L, Boyers, A, Chadwick, A, Stratford, I

Get full text

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model by WILLIAMS, K. J, TELFER, B. A, STRATFORD, I. J, WEDGE, S. R

“…The effect of ZD1839 ('Iressa'), a specific inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor, on the radiation response of…”
Get full text

Anticancer chemosensitization and radiosensitization by the novel Poly(ADP-ribose) polymerase-1 inhibitor AG14361 by CALABRESE, Christopher R, ALMASSY, Robert, LI, Jianke, MAEGLEY, Karen, NEWELL, David R, NOTARIANNI, Elena, STRATFORD, Ian J, SKALITZKY, Donald, THOMAS, Huw D, WANG, Ian-Zhen, WEBBER, Stephen E, WILLIAMS, Kaye J, BARTON, Stephanie, CURTIN, Nicola J, BATEY, Michael A, CALVERT, A. Hilary, CANAN-KOCH, Stacie, DURKACZ, Barbara W, HOSTOMSKY, Zdenek, KUMPF, Robert A, KYLE, Suzanne

“…Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks. Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy…”
Get full text

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial by Marti, F.E. Marti, Jayson, G.C., Manoharan, P., O'Connor, J., Renehan, A.G., Backen, A.C., Mistry, H., Ortega, F., Li, K., Simpson, K.L., Allen, J., Connell, J., Underhill, S., Misra, V., Williams, K.J., Stratford, I., Jackson, A., Dive, C., Saunders, M.P.

“…The DREAMtherapy (Dual REctal Angiogenesis MEK inhibition radiotherapy) trial is a novel intertwined design whereby two tyrosine kinase inhibitors (cediranib…”
Get full text

Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth by Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., Ratcliffe, P. J.

“…Recent studies of tissue culture cells have defined a widespread system of oxygen-regulated gene expression based on the activation of a heterodimeric…”
Get full text

Treatment with the novel Akt inhibitor AZD5363 following radiotherapy improves tumour control in mouse models of head and neck cancer by Searle, E, Telfer, B, Forster, D, Williams, K, Davies, B, Illidge, T, Stratford, I

Get full text

Statin-induced metabolic modulation in cancer: a biomarker for targeting monocarboxylate transporters by Mehibel, M, Ortiz-Martinez, F, Boyers, A, Telfer, B, Williams, K, Stratford, I

Get full text

PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia by Xenaki, G, Ontikatze, T, Rajendran, R, Stratford, I J, Dive, C, Krstic-Demonacos, M, Demonacos, C

“…The p53 tumour suppressor is involved in several crucial cellular functions including cell-cycle arrest and apoptosis. p53 stabilization occurs under hypoxic…”
Get full text

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells by Roberts, D L, Williams, K J, Cowen, R L, Barathova, M, Eustace, A J, Brittain-Dissont, S, Tilby, M J, Pearson, D G, Ottley, C J, Stratford, I J, Dive, C

“…Background: Hypoxia is as an indicator of poor treatment outcome. Consistently, hypoxic HCT116 colorectal cancer cells are resistant to oxaliplatin, although…”
Get full text

Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies by Oliver, R.J., Woodwards, R.T.M., Sloan, P., Thakker, N.S., Stratford, I.J., Airley, R.E.

“…Hypoxia in tumours of the oral cavity has not been extensively investigated with regard to clinical outcome and prognosis. The expression of the facilitative…”
Get full text

Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy by Searle, E.J, Illidge, T.M, Stratford, I.J

“…Abstract Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy…”
Get full text

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy by GRIFFITHS, L, STRATFORD, I. J

“…Angiogenesis plays an important role in the growth and metastasis of solid tumours. Platelet-derived endothelial cell growth factor (PD-ECGF) is known to be…”
Get full text

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2 by Nolan, K.A., Humphries, M.P., Bryce, R.A., Stratford, I.J.

“…Electrostatic surface representation of NQO2 with NSC660841 docked in the binding pocked. NSC660841 is identified as the most potent inhibitor of NQO2 yet…”
Get full text

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy by Lunt, S J, Cawthorne, C, Ali, M, Telfer, B A, Babur, M, Smigova, A, Julyan, P J, Price, P M, Stratford, I J, Bloomer, W D, Papadopoulou, M V, Williams, K J

“…Background: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of…”
Get full text

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN™; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts by WILLIAMS, K. J, TELFER, B. A, SHANNON, A. M, BABUR, M, STRATFORD, I. J, WEDGE, S. R

“…A number of pre-clinical studies have suggested that blocking vascular endothelial growth factor (VEGF) signalling can be beneficial in combination with…”
Get full text

Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance by Erler, Janine T., Cawthorne, Christopher J., Williams, Kaye J., Koritzinsky, Marianne, Wouters, Bradley G., Wilson, Clare, Miller, Crispin, Demonacos, Costas, Stratford, Ian J., Dive, Caroline

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent by PATTERSON, L. H, MCKEOWN, S. R, RUPARELIA, K, DOUBLE, J. A, BIBBY, M. C, COLE, S, STRATFORD, I. J

“…AQ4 (1,4-Bis-[[2-(dimethylamino-N-oxide)ethyl]amino]5,8-dihydroxyanthrace ne-9, 10-dione) is a prodrug designed to be excluded from cell nuclei until…”
Get full text